The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.1%, and the actively t
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
Solo titulares de alta señal — eventos macro, earnings, M&A, regulación. Listicles y clickbait de analistas filtrados por defecto. Refrescado cada hora.
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.1%, and the actively t
ImmunityBio (IBRX) delivered earnings and revenue surprises of -12.50% and +7.56%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
IBRX's Q1 outlook rides on Anktiva's surging uptake, with preliminary revenues showing triple-digit growth ahead of its earnings report later this month.